News Story Headlines
March 26, 2025
Intellia Therapeutics Announces FDA Regenerative Medicine Advanced Therapy (RMAT) Designation Granted to Nexiguran Ziclumeran (nex-z) for the Treatment of Transthyretin (ATTR) Amyloidosis with Cardiomyopathy
CAMBRIDGE, Mass., March 26, 2025 (GLOBE NEWSWIRE) — Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based therapies, today announced that the U.S....
March 21, 2025
Alnylam Announces FDA Approval of AMVUTTRA® (vutrisiran), the First RNAi Therapeutic to Reduce Cardiovascular Death, Hospitalizations and Urgent Heart Failure Visits in Adults with ATTR Amyloidosis with Cardiomyopathy (ATTR-CM)
Mar 20, 2025
− Novel Mechanism of Action Delivers Rapid Knockdown of Transthyretin, Addressing the Disease at its Source –
− Proven Consistency of Effect on Cardiovascular Outcomes, Function, and...
February 26, 2025
Mystery Solved: New Research Reveals Why a Key Protein Turns Deadly in Aging Bodies
Mystery Solved: New Research Reveals Why a Key Protein Turns Deadly in Aging Bodies
By Scripps Research Institute
January 30, 2025
These insights could drive the development of...
February 26, 2025
An Unexpected Benefit of Adding the Patient Voice to Medical Education—Train Providers to Be Better
An Unexpected Benefit of Adding the Patient Voice to Medical Education—Train Providers to Be Better
Mackenzie N. Boedicker, MS, BS & Deborah D. Boedicker, MBA, BS
Published online January...
February 20, 2025
Light the Night for Amyloidosis 2025
“Light the Night for Amyloidosis” is an awareness campaign designed to raise awareness about the symptoms, diagnosis, treatment, and potential cure for amyloidosis. In honor of ‘Amyloidosis Awareness Month’ in...